KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Study Protocol of OLIGOPELVIS 2-GETUG P12: A Randomized Phase 3 Study Comparing Intermittent Androgen-deprivation Therapy with or Without Salvage High-dose Intensity-modulated Radiotherapy to Oligorecurrent Pelvic and Para-aortic Lymph Nodes in Patients with Biochemically Relapsing Prostate Cancer.

Quentin Josset, Audrey Blanc-Lapierre, Grégoire Pigne, Lysian Cartier, David Pasquier, Philippe Ronchin, Guillaume Bera, Ali Hasbini, Benjamin Schipman, Jonathan Khalifa, Paul Sargos, Magali Quivrin, Ulrike Schick, Frédéric Mallet, Cecile Laude, Clotilde Morand, Geneviève Loos, Loig Vaugier, Ke Zhou, Nathalie Mesgouez-Nebout, Stéphane Supiot

Eur Urol Oncol S2588-9311(26)00113-6

PMID42276876
PMCID-
DOI10.1016/j.euo.2026.04.009
发表日期2026-06-11
AI 判定为临床试验方案/Protocol,尚非正式结果论文;因此未进入 KM Figure 抓取。
摘要

摘要

BACKGROUND: The management of oligorecurrent pelvic lymph nodes in patients with prostate cancer is debated. Intermittent androgen-deprivation therapy (ADT; IADT) is often proposed. Elective pelvis irradiation (ENRT) may prolong tumor control and decrease subsequent spread. OBJECTIVE: To assess the efficacy of a combination of 6 mo of IADT with or without ENRT to treat patients with oligorecurrent pelvic and para-aortic lymph nodes of prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: The OLIGOPELVIS 2-GETUG P12 trial is a multicenter randomized phase 3 trial, randomizing patients with 1-5 oligorecurrent pelvic and/or para-aortic lymph nodes of prostate cancer between arm A (IADT alone for 6 mo) versus arm B (salvage pelvic image-guided intensity-modulated radiotherapy [IG-IMRT], 54 Gy, 30 fractions to the pelvis and 66 Gy, 30 fractions to the lymph nodes) combined with IADT). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary outcome is progression-free survival, defined as the time from randomization until a biochemical-clinical failure is detected or death from any cause. In total, 256 patients will be included. RESULTS AND LIMITATIONS: In this population of patients requiring ADT, ENRT may demonstrate antitumoral efficacy while achieving acceptable toxicity and maintaining quality of life. Limitations are mainly inherent to the open-label design of this study. CONCLUSIONS: This phase 3 study will explore the role of salvage pelvic IG-IMRT combined with IADT in patients with oligorecurrent pelvic lymph nodes of prostate cancer in prolonging the first failure-free interval between the first and the second IADT courses. PATIENT SUMMARY: The OLIGOPELVIS 2-GETUG P12 clinical trial assesses short-term (6 mo) androgen-deprivation therapy in association with external beam radiation therapy in men with prostate cancer relapsing to pelvic and para-aortic lymph nodes of prostate cancer. The trial investigates whether radiotherapy targeting pelvic and para-aortic lymph nodes can improve the biological response while maintaining a favorable tolerability profile. TRIAL REGISTRATION: NCT03630666, RCB 2018-A00551-54, date of registration: 2018-12-04.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。